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Abstract
Background: In randomised clinical trials involving time-to-event outcomes, the failures concerned may be events
of an entirely different nature and as such define a classical competing risks framework. In designing and analysing
clinical trials involving such endpoints, it is important to account for the competing events, and evaluate how each
contributes to the overall failure. An appropriate choice of statistical model is important for adequate
determination of sample size.
Methods: We describe how competing events may be summarised in such trials using cumulative incidence
functions and Gray’s test. The statistical modelling of competing events using proportional cause-specific and
subdistribution hazard functions, and the corresponding procedures for sample size estimation are outlined. These
are illustrated using data from a randomised clinical trial (SQNP01) of patients with advanced (non-metastatic)
nasopharyngeal cancer.
Results: In this trial, treatment has no effect on the competing event of loco-regional recurrence. Thus the effects
of treatment on the hazard of distant metastasis were similar via both the cause-specific (unadjusted csHR = 0.43,
95% CI 0.25 - 0.72) and subdistribution (unadjusted subHR 0.43; 95% CI 0.25 - 0.76) hazard analyses, in favour of
concurrent chemo-radiotherapy followed by adjuvant chemotherapy. Adjusting for nodal status and tumour size
did not alter the results. The results of the logrank test (p = 0.002) comparing the cause-specific hazards and the
Gray’s test (p = 0.003) comparing the cumulative incidences also led to the same conclusion. However, the
subdistribution hazard analysis requires many more subjects than the cause-specific hazard analysis to detect the
same magnitude of effect.
Conclusions: The cause-specific hazard analysis is appropriate for analysing competing risks outcomes when
treatment has no effect on the cause-specific hazard of the competing event. It requires fewer subjects than the
subdistribution hazard analysis for a similar effect size. However, if the main and competing events are influenced
in opposing directions by an intervention, a subdistribution hazard analysis may be warranted.
Background
In a randomised, double-blind, three-period clinical trial
of lisinopril in patients with chronic heart failure [1],
factors associated with different modes of cardiovascular
death were investigated to guide physicians in their
treatment decisions. In this trial, sudden death was con-
sidered as a competing risk for chronic heart-failure
death, and hence it was important to distinguish
between factors that were associated with increased
mortality and factors which were simply markers of a
worse prognosis.
Similarly, in trials designed to delay or avoid irradia-
tion among children with malignant brain tumour,
although irradiation following disease progression is an
important event, competing events include declining
radiotherapy (RT) following disease progression or elec-
tive RT despite no evidence of disease progression. In
order to accurately describe the cumulative need for RT
and evaluate how each event contributes to the delay or
advancement of irradiation in such instances, it is vital
to account for these competing events via a competing
risks analysis [2,3].
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competing risks outcomes using the Kaplan-Meier (KM)
method of survival analysis. However, the KM method
does not evaluate how each event contributes to the
overall failure. Besides, it relies on the stringent assump-
tion of independence between different event types and
overestimates the event-specific failure probabilities.
In this paper, we describe how clinical trials involving
competing risks outcomes may be analysed and
designed using data from a randomised clinical trial
(SQNP01) of patients with nasopharyngeal cancer
(NPC) as illustration [4].
Competing Risks in Cancer Studies
Under the classical competing risks framework, a subject
m a yb es i m u l t a n e o u s l ye x p osed to several distinct
events, but may eventually only fail from one of these.
In such settings, the occurrence of a specific event
would preclude the competing risks from being
observed. In cancer clinical trials for example, the main
outcome is usually death (D), although local recurrence
(R), distant metastasis (M) and second malignancy (S)
are always of relevance. For some patients the full path
from randomisation to death can be recorded. However,
if D occurs first, then only the time to death from ran-
domisation, tD, will be recorded, and the times to the
other events tR, tM and tS will not be observed. Similarly,
if M occurs before the other events are observed, then
this may potentially initiat eac h a n g ei nt h e r a p e u t i c
strategy and hence change the course of the disease.
Thus, in cancer clinical trials, the first event is usually of
interest, and as such, competing risks modelling focus
on the occurrence of the first event even in cases where
multiple events (for example, local recurrence followed
by distance metastasis) can occur. This is because the
additional complexity of analysing such data does not
often yield a materially different conclusion [5,6].
Illustrative Trial
T h eo b j e c t i v eo ft h eS Q N P 0 1t r i a lw a st oe v a l u a t et h e
role of chemo-RT and adjuvant chemotherapy using
combination chemotherapy comprising cisplatin (CDDP)
and 5-Fluorouracil (FU) with RT in treating patients
with locally advanced NPC [4]. All patients received a
standard course of RT to a dose of 70Gy in 35 fractions.
For patients randomised to receive chemo-RT followed
by adjuvant chemotherapy (CRT), three cycles of con-
current CDDP (25 mg/m
2/d for 4 days) were adminis-
tered on weeks 1, 4 and 7 of RT. A further three cycles
of adjuvant chemotherapy comprising CDDP (20 mg/
m
2/d for 4 days) and 5-FU (1,000 mg/m
2/d for 4 days)
were administered between weeks 11 and 19.
The primary outcome of this trial was overall survival,
and the trial was designed on the basis of detecting a
difference in absolute survival at 2 years of 25%. This
assumed a survival rate was 55% for RT alone and 80%
for CRT, a two-sided test size of 5% and a power of 90%.
In this randomised clinical trial, distant metastasis was
considered to be an important secondary outcome
because it has been shown that about 50% of patients
with very large and/or supraclavicular lymph nodes will
relapse distantly [7] even after a full course of irradiation.
For simplicity of illustration, we consider distant
metastasis (M) as the main event of interest, and only
one competing risk, loco-regional recurrence (R). The
latter includes relapses at the primary site and the neck.
If we consider only the first event that occurs, such a
classification fits naturally into the competing risks fra-
m e w o r k ,w h e r eas u b j e c tm a yo n l yf a i lf r o mo n eo f
these two causes (Figure 1).
Methods
Statistical Terminology
Kaplan-Meier event-free survival (EFS) estimates
In cancer clinical trials, a patient may experience treat-
ment failure as a consequence of the recurrence of the
primary disease at the local site or development of dis-
tant metastases. The event free survival (EFS) time, tj,i s
often measured from the date of randomisation to the
date of first occurrence of any of these failure types.
Assuming these events to be independent, the event-
free survival probability may be estimated as
EFS

tj

= EFS

tj−1


1 −
dj
nj

.
The probability of being event-free at time tj, EFS(tj)i s
calculated from EFS(tj-1), the probability of being event-
free at tj-1, nj t h en u m b e ro fp a t i e n t sw h oa r ef r e ef r o m
any event just before tj and dj the number of events at tj.
Cause-specific hazard function
T h et y p eo ff a i l u r e si ss o m e t i m e sd e s c r i b e du s i n gt h e
cause-specific hazard function, hl(tj), which in the con-
text of competing risks, can be separately estimated for
each event type l, as follows
hl

tj

=
dlj
nj
.
Distant metastasis (M)
Remission 
Loco-regional recurrence (R)
Figure 1 A competing risks model for the SQNP01 trial.
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just before tj and dlj the number who fail from event l
at tj.
Cumulative incidence or subdistribution
The Cumulative Incidence (CMI), also referred to as a
subdistribution, estimates the event-specific probability
of each event, in the presence of all other competing
risks [8]. For an event of type l, it is estimated by
CMIl

tj

=

all j, tj≤t
EFS

tj−1

hl

tj

,
and may be expressed as
CMIl

tj

= CMIl

tj−1

+ EFS

tj−1

hl

tj

.
For large time, the subdistribution’s limit is the preva-
lence of the event of interest.
Logrank and Gray’s tests
The logrank test is widely used for comparing cause-
specific hazards between groups of clinical interest. It
censors the competing events at the time of occurrence
of the main event. Considering two treatments for
example RT and CRT in the SQNP01 trial, this test
assumes the null hypothesis hl, RT (t)=hl, CRT (t), and
hence a hazard ratio (HR)o f1 .T h eHR m a yb ee s t i -
mated by
HR =
OCRT/ECRT
ORT/ERT
,
where OCRT and ECRT refers to the observed and
expected number of events amongst patients receiving
CRT and ORT and ERT are the corresponding events for
those receiving RT. Since the estimate of HR is not nor-
mally distributed, its 95% confidence interval (CI) may
be estimated via log HR assuming
SE

logHR

=

1
ECRT
+
1
ERT

[9].
The Gray’s test [10] has been advocated to compare
the cumulative subdistribution hazard that has a one-to-
one relation with the cumulative incidence. The subdis-
tribution hazard function is defined by
hl (t) = −
d
dt
log{1 − CMIl (t)}.
Incorporating prognostic factors
In the SQNP01 trial, nodal status and tumour size could
also influence survival outcomes, and hence it is impor-
tant to account for them when evaluating the extent of
treatment difference. Various regression models have
been proposed to relate the cause-specific hazard or the
CMI to covariates [11-13]. We discuss two proportional
(namely the cause-specific and subdistribution) hazard
models for analysing competing risks data.
Cause-specific Cox model
Suppose for simplicity, we consider two event types, a
main event of interest, Event M, and a competing risk,
Event R,w i t has e to fp covariates, x1, ..., xp. The Cox
proportional hazards model which is frequently used for
modelling the hazard of a single failure may be extended
to model the cause-specific hazard for Event M as fol-
lows:
hM(t)=h0M(t)exp(βM1x1+βM2x2 + ...+ βMpxp), (1)
where h0M(t) is the baseline hazard of Event M,a n d
exp(bM1), exp(bM2), ..., exp(bMp) are the cause-specific
hazard ratios (csHR) which measure the effect of the
respective covariates on Event M, taking the competing
event, Event R, as censored [8]. The cause-specific
hazard for Event R is similarly formulated.
Modelling subdistribution hazards
It has been argued that the cause-specific Cox analysis is
not adequate for modelling competing risks data
because it censors the competing events [14]. Such cen-
soring is assumed to be non-informative, and this proce-
dure fails to consider that those who have experienced a
competing event can never experience the main event of
interest. As the effect of covariates on the cause-specific
h a z a r d sd o e sn o tt r a n s l a t et oa ne f f e c to nt h ec u m u l a -
tive incidence, Fine and Gray have proposed modelling
of the CMI based on the proportional subdistribution
hazards model [11]. This model allows the incorporation
of the effects of multiple risk factors, whereas the Gray’s
test [10] considers the impact of only a single prognostic
factor. Based on the subdistribution hazard model, if an
individual experiences the competing event instead of
the main event, it is assumed that he remains in the risk
set forever, and so his main event time is infinite.
The subdistribution hazard model is formulated in a
similar manner as the cause-specific Cox model shown
earlier, except that the exponential of the regression
coefficients now denote the subdistribution hazard ratios
(subHR) of the respective covariates on the subdistribu-
tion hazard of event M, for example.
Sample size estimation
Sample size estimation procedures for both the cause-
specific and subdistribution hazard models are based on
the Schoenfeld formula for the Cox model [15]. Two
key parameters need to be specified: (i) planned hazard
ratio (HRPlan) that quantifies the treatment effect, and
(ii) anticipated proportion of failures from the main
event of interest (ΨPlan).
Assuming an experimental (CRT) and a standard (RT)
treatment, the benefit of CRT over RT for the event of
interest may be expressed in terms of either subHR or
Tai et al. Trials 2011, 12:127
http://www.trialsjournal.com/content/12/1/127
Page 3 of 10csHR, depending on the choice of statistical model. The
total number of events, e, assuming Type I and Type II
errors of a and b respectively, can be expressed as
e =
(zα/2 + zβ)
2
(lnHRPlan)
2pCRT(1 − pCRT)
, (2)
where zg denotes the upper g-quantile of the standard
Normal distribution, pCRT the proportion randomised to
receive CRT and ln HRPlan the natural logarithmic form
of the anticipated effect size. In the absence of censor-
i n g ,t h et o t a ls a m p l es i z e ,n, equals the number of (say
type M) events observed, while in the presence of cen-
soring,
n =
e
 Plan
. (3)
Estimation based on subdistribution hazard model
The Schoenfeld formula [15] has been extended to esti-
mate sample size for modelling CMI via the subdistribu-
tion hazard by Latouche et al.[ 1 6 ]I ft h e r ew e r en o
censored observations, ΨPlan reduces to the CMI at time
t for the main event, that is CMIM(t), in the SQNP01
trial. In the presence of censoring, ΨPlan m a yb ee s t i -
mated by (1 - c)CMIM(t), where c is the anticipated pro-
portion of censored observations [16].
Estimation based on cause-specific hazard model
Pintilie proposed the Cox model to estimate sample size
when testing the effect of a covariate on the cause-speci-
fic hazard in the presence of competing risks [17]. The
times to the main and competing events were assumed
to be independent and exponentially distributed. In the
context of a randomised clinical trial, it is further
assumed that treatment affects the cause-specific hazard
of the main but not the competing event [17,18].
The anticipated probability of the main event M,
ΨPlan, may be expressed in terms of the hazard functions
by
 Plan =
λM
λ
×

1 −
exp(−λf) − exp(−λ × (f + a))
λa

, (4)
where lM denotes the cause-specific hazard of main
event M, l the total hazard of both events, a the accrual
duration and f the additional follow-up period.
As Pintilie has shown [17], the cause-specific hazard
for our main event M m a yb ed e r i v e df r o mt h eCMI as
follows:
λM = CMIM ×
−ln(1 − CMIM − CMIR)
T(CMIM + CMIR)
, (5)
where CMIM and CMIR represent the CMI of the
respective events at time T, the total study duration.
The cause-specific hazard for the competing event, lR
can be similarly obtained.
The sample size may be estimated as before, but the
treatment effect is now expressed by ln csHR when esti-
mating e, the expected number of events. Pintilie [17]
and Machin et al. [19] have developed software for esti-
mating sample size and power based on the cause-speci-
fic hazard method.
Schulgen et al. [20] have proposed a similar method to
estimate the sample size for clinical trials involving
time-to-event competing risks outcomes based on a
multi-state model, assuming a time-homogeneous Mar-
kov process. The probability of observing an event of
type M by time t is given by
PM (t) =
λM
λ
(1 − exp(−λt)); λ = λM + λR.
This is essentially equation (2) of Pintilie [17], the
cumulative incidence function of M i nt h ep r e s e n c eo f
competing risks. Based on the cumulative incidence
probability of the event of interest and the cumulative
incidence probability of the competing risks, Pintilie [17]
obtained the solution of the system for the cause-specific
hazard as shown in equation (5) above. As the formula-
tion of the anticipated probability in Schulgen et al [20]
is the same as that presented by Pintilie and is as shown
in equation (4) above, and with both methods assuming
constant cause-specific hazard rates, we expect the two
approaches to yield the same sample size estimates when
the same parameters are specified in the estimation.
Results
Between September 1997 and May 2003, a total of 221
patients were randomised to receive RT alone (n = 110) or
CRT (n = 111) [4]. Relapse at first site were documented
in a total of 75 patients: 19 loco-regional and 56 distant
metastases (Figure 2). In particular, distant metastasis
(event M) occurred in 38 patients who received RT and 18
CRT. Ten patients in RT as compared with 9 in CRT
experienced loco-regional recurrence (event R).
Estimating cause-specific hazard and cumulative
incidence
In Table 1, we illustrate computational details of the
cause-specific hazard as well as the cumulative incidence
for event R amongst those receiving CRT of the
SQNP01 clinical trial. The time to event R is denoted in
column (2). For example, the first subject experienced
this event at Day 153 post treatment, while for the sec-
ond subject, it occurred at Day 248. Tied occurrences of
event R were not reported, and so dRj = 1 at each event
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(tj), by dividing dRj, the number in column (3) by nj,t h e
number in column (4). In column (7), we obtain CMIR
(tj)=CMIR(tj-1)+EFS(tj-1)×hR(tj). For j =9 ,CMIR(t9)
= CMIR(t8)+EFS(t8)×hR(t9) = 0.0760 + 0.7131 ×
0.0667 = 0.1235.
Comparing logrank and Gray’s tests
Using the logrank test to evaluate the treatment effect
on the cause-specific hazards, a beneficial effect of CRT
on event M was suggested (HR = 0.43, 95% CI 0.25 -
0.72; p = 0.002). However, the treatment effect was not
detected for event R (HR = 0.84, 95% CI 0.34 - 2.07; p =
0.711) (Table 2).
The 2-year cumulative incidence of event M was
notably lower in the CRT arm as compared with RT
(13.3% versus 30.8%). Consistent with the logrank test,
the Gray’s test showed a beneficial treatment effect on
event M in favour of CRT (p = 0.003) (Figure 3). How-
ever, the 2-year cumulative incidences of event R were
similar for both treatments (8.8% versus 7.6%). Again,
the result of Gray’st e s t( p =0 . 8 3 4 )c o n c u r r e dw i t ht h e
logrank test.
Cause-specific hazard analysis
The impact of other patient related factors cannot be
readily accounted for using the logrank test. Hence,
since known risk factors influencing survival outcomes
of the SQNP01 trial include nodal status and tumour
size, we further adjust for these prognostic variables via
the cause-specific Cox model. Table 3 shows that the
unadjusted csHR estimates comparing treatment for
both the logrank test and cause-specific Cox model do
not differ appreciably. The unadjusted csHR and
adjusted csHR estimates suggest reduced hazards of dis-
tant metastasis among patients randomised to receive
CRT (Tables 3 and 4). Adjusting for nodal status and
tumour size did not alter the estimates materially (unad-
justed csHR = 0.43 versus adjusted csHR = 0.39).
As for loco-regional recurrence, there was no evidence
of treatment effect (unadjusted csHR = 0.84; 95% CI
0.34 - 2.08). Although an attenuated effect was observed
after adjusting for nodal status and tumour size
(adjusted csHR = 0.69; 95% 0.27 - 1.79), statistical
Table 1 Cumulative incidence for event R (loco-regional
recurrence) of the SQNP01 trial
j
(1)
tj
(2)
dRj
(3)
nj
(4)
hR(tj)
(5)
EFS(tj-1)
(6)
CMIR(tj)
(7)
0 0 0 111 0.0000 1.0000 0.0000
1 153 1 109 0.0092 1.0000 0.0092
2 248 1 100 0.0100 0.9261 0.0184
3 274 1 95 0.0105 0.8888 0.0278
4 277 1 94 0.0106 0.8794 0.0372
5 295 1 93 0.0108 0.8701 0.0465
6 367 1 91 0.0110 0.8513 0.0559
7 399 1 86 0.0116 0.8326 0.0655
8 524 1 78 0.0128 0.8130 0.0760
9 1660 1 15 0.0667 0.7131 0.1235
Table 2 Cause-specific hazard ratio (HR) comparing CRT
versus RT for each competing event based on the
logrank test
Variables OE Unadjusted HR
(95% CI)
p-
value
M: Distant metastasis
RT 38 26.54 0.43 (0.25 - 0.72) 0.002
CRT 18 29.46 1.00
R: Loco-regional
recurrence
RT 10 9.19 0.84 (0.34 - 2.07) 0.711
CRT 9 9.81 1.00
+ adjuvant chemo 
221 randomised 
110 radiotherapy (RT) 
18 distant 
metastasis 
38 distant 
metastasis 
62 no evidence of 
relapse 
111 concurrent chemo-RT + 
adjuvant chemotherapy (CRT)
91 no evidence of 
relapse 
9 loco-regional 
relapse 
10 loco-regional 
relapse 
Figure 2 Progress of 221 patients enrolled in the SQNP01 trial.
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in terms of the rate of tumour progression, patients who
received CRT have lower rates of distant metastasis and
loco-regional recurrence.
Subdistribution hazard analysis
In the SQNP01 trial, it is important to quantify the pro-
portion of NPC patients who experienced distant metas-
tasis in order to target therapeutic strategy at this
a.
Number at risk (Event)
RT 110 (0) 83 (14) 51 (17) 34 (3) 20 (2) 5 (2)
CRT 111 (0) 91 (11) 65 (3) 44 (2) 24 (2) 11 (0)
b.
Number at risk (Event)  
RT 110 (0) 83 (6) 51 (3) 34 (0) 20 (0) 5 (1)
CRT 111 (0) 91 (5) 65 (3) 44 (0) 24 (0) 11 (1)
RT
CRT
Unadjusted HR: 0.43 (95% CI: 0.25 – 0.72; Logrank p = 0.002)
Gray’s p = 0.003
Unadjusted HR: 0.84 (95% CI: 0.34 – 2.07; Logrank p = 0.711)
Gray’s p = 0.834
RT
CRT
Figure 3 Cumulative incidence of relapse amongst patients in RT (solid line) and CRT (dashed line) for (a) Event M: Distant metastasis,
(b) Event R: Loco-regional recurrence. HR = Hazard Ratio; CI = Confidence Interval.
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hazard which directly quantifies the proportion rather
than the cause-specific hazard which describes the rate
in which a patient develop distant metastasis, would be
more appropriate for addressing this objective. The sub-
distribution hazards analysis was implemented in
STATA version 11 using the command stcrreg [21]. As
before, we adjust for nodal status and tumour size when
assessing treatment effect on the cause-specific subdis-
tribution hazards. The unadjusted results considering
only treatment are also presented for comparison in
Table 3.
In keeping with the cause-specific hazard analysis, the
subdistribution hazard analysis also suggested significant
reduction in subdistribution hazard for event M
amongst those receiving CRT (unadjusted subHR 0.43;
95% CI 0.25 - 0.76), and no treatment effect on event R
(unadjusted subHR 0.91; 95% CI 0.37 - 2.24) (Table 3).
This is consistent with our analysis comparing CMI via
the Gray’s test, which showed reduction in CMI of M
(13.3% versus 30.8%) amongst patients receiving CRT
and no difference in CMI of R (7.6% versus 8.8%)
between the two groups (Figure 3).
For event M, the results remain unaltered after adjust-
ing for nodal status and tumour size, with adjusted
subHR = 0.42 (95% CI 0.23 - 0.79) (Table 4). In the case
of event R, a larger but non-significant effect was
observed (adjusted subHR = 0.81; 95% CI 0.30 - 2.17).
This implies that patients on CRT were less likely to
have distant metastasis, but the beneficial effect of CRT
on loco-regional recurrence was not evident.
Designing a randomised clinical trial with competing risk
outcomes
Planning
For the expository purpose of illustrating the methods
for designing a clinical trial with competing risks out-
comes, we suppose at the study planning, the investiga-
tor postulated that the treatment effect on event M was
similar in magnitude to what was found in the literature,
based on the SQNP01 trial. He further assumes equal
allocation between treatments (ie. p = 0.5), and plans for
a power of 80% and a two-sided test of 5% correspond-
ing to Z0.2 =0 . 8 4a n dZ0.025 = 1.96 from the standard
Normal table.
Subdistribution approach
Deciding a priori that the subdistribution hazard analy-
sis will be implemented, and anticipating that CRT
would reduce the hazard of event M with subHR =0 . 4 3
as in Table 3, then applying equation (2), the number of
events required is
e =
(z0.025 + z0.2)
2
(ln0.43)
20.5(0.5)
=
( 1 . 9 6+0 . 8 4 )
2
0.1781
=4 5 .
Suppose the investigator assumes the 5-year CMI of
event M is similar to that observed in the SQNP01 trial,
that is, CMIM = 0.35, CMIM+R = 0.47, and so the cen-
sored cases c = 1 - 0.47 = 0.53 at 5-year. From these,
ΨPlan can be estimated by (1 - c)CMIM = 0.47 × 0.35 =
0.1645. Thus based on equation (3), the total required
sample size is
n =
45
0.1645
= 274.
Cause-specific approach
Suppose the investigator chooses instead to measure the
effect of treatment on the main event M using the
cause-specific hazard, and assumes csHR = 0.43 which is
similar in magnitude to subHR (Table 2). Using equa-
tion (2), the expected number of events remains
unchanged, that is e = 45.
We further assume that the 5-year CMI of event M in
RT and CRT are 0.45 and 0.2 respectively, and that of
event R in both groups is 0.12, with accrual duration a
= 4 years, additional follow-up period f = 1 year, and
total study duration, T = a + f = 5 years. To estimate,
ΨPlan, the probability of the main event M in the RT
group, we derive its cause-specific hazard from the 5-
year CMI using equation (5):
Table 3 Logrank and Cox cause-specific hazard ratios
(csHR), subdistribution hazard ratios (subHR) and
associated 95% confidence intervals for evaluating the
treatment effect
Unadjusted csHR Unadjusted
subHR
Competing event Logrank Cox Subdistribution
M: Distant metastasis 0.43
(0.25 - 0.72)
0.43
(0.24 - 0.75)
0.43 (0.25 - 0.76)
R: Loco-regional
recurrence
0.84
(0.34 - 2.07)
0.84
(0.34 - 2.08)
0.91 (0.37 - 2.24)
Table 4 Cox cause-specific hazard ratios (csHR),
subdistribution hazard ratios (subHR), and associated
95% confidence intervals for evaluating the treatment
effect; adjusted for nodal status and both tumour size
Adjusted for nodal status and tumour
size
Competing event csHR subHR
M: Distant metastasis 0.39 (0.22 - 0.71) 0.42 (0.23 - 0.79)
R: Loco-regional recurrence 0.69 (0.27 - 1.79) 0.81 (0.30 - 2.17)
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−ln(1 − 0.45 − 0.12)
5(0.45 + 0.12)
= 0.1333.
We derive lM, CRT = 0.0482, lR, RT = 0.0355 and lR,
CRT = 0.0289, similarly. Since lRT = 0.1333 + 0.0355 =
0.1688, from equation (4), the expected proportion of
failures due to the main event M in the RT arm is
 Plan,RT =
0.1333
0.1688
×

1 −
exp(−0.1688 × 1) − exp(−0.1688 × 5)
0.1688 × 4

= 0.3047.
Similarly, the expected proportion of failures due to
the main event M in the CRT arm is
 Plan,CRT =
0.0482
0.0771
×

1 −
exp(−0.0771 × 1) − exp(−0.0771 × 5)
0.0771 × 4

= 0.1271.
Thus, ΨPlan =p CRT ΨPlan, CRT +( 1 -p CRT) ΨPlan, RT =
0.5(0.3047) + 0.5(0.1271) = 0.2159.
From equation (3), the total sample size required via
the cause-specific hazard analysis is thus
n =
45
0.2159
= 209.
This is notably less than the size of the trial which was
designed assuming a subdistribution hazard model.
Sample size estimation for other effect sizes
Table 5 illustrates sample size for a range of effect sizes
corresponding to those observed for nodal status and
tumour size in patients with locally advanced NPC. The
number of events and samples sizes required increase
rapidly for a range of effect sizes for subHR from 0.39
to 0.75. Although similar effects were observed for both
analyses, a larger sample size was required for the sub-
distribution hazard analysis.
Discussion
Under the classical competing risks framework, a subject
m a yb es i m u l t a n e o u s l ye x p osed to several distinct
events, but may eventually only fail from one of these.
In such settings, the occurrence of a specific failure type
would preclude the competing events from being
observed. The cumulative incidence estimates have been
advocated to summarise competing risks data
[5,8,9,12,22]. This approach appropriately accounts for
each competing risk, and provides an unbiased estimate
in terms of event-specific probability.
In randomised clinical trials involving competing risks,
the treatment effect on the cause-specific hazard is
sometimes evaluated via the logrank test. However, its
use is controversial [23,24]. This method censors the
competing events at the time of occurrence of the main
event. It also assumes that treatment has no effect on
the hazards of competing risks [17,18]. Thus its use may
only be appropriate if the objective is to measure the
effect of treatment on a specific failure, in isolation of
other competing events.
In practice, the cumulative incidence curves are more
relevant for explaining the relative impact of therapies
to a patient. Using the SQNP01 trial data, the compet-
ing risks method found 13% of patients in CRT develop-
ing distant metastasis at 2-year as compared to 31% in
RT. The 2-year cumulative incidence of loco-regional
recurrence hovered around 8% for both treatments. In
these instances, the results of both logrank and Gray’s
tests concurred.
The subdistribution hazard model estimates the effect
of treatment on the CMI of each event, while incorpor-
ating the effects of other relevant covariates. In trials
designed to evaluate the role of treatment on disease
recurrence, it is important to evaluate the contribution
to failure by each event. The CMI which quantifies the
cause-specific probability provides a more direct mea-
sure of the overall failure rate than the cause-specific
hazard.
Consistent with the assumption of no treatment effect
on the hazards from competing risks when implement-
ing the cause-specific hazards analysis [25], we found
the two models to concur well for the SQNP01 data. A
beneficial effect of CRT on the cause-specific hazard
was observed for distant metastasis, but it had no effect
on the competing event of loco-regional recurrence. In
this instance, both the cause-specific and subdistribution
hazard analyses showed CRT reduces the hazard of dis-
tant metastasis by the same extent (57%).
Nevertheless, it should be noted that differences
between the cause-specific and subdistribution hazard
ratios may be appreciable if the main and competing
events are influenced in opposite directions by an inter-
vention [3,26,27]. Williamson et al.[ 2 4 ]h a v es h o w n
that in such instances, the Gray’s test comparing CMI
has greater power than the log-rank test comparing the
cause-specific hazard to detect treatment differences,
and so a subdistribution hazard analysis may be
warranted.
The choice between the two models has implications
on the study design. As reported by Latouche and
Porcher [18] and illustrated using the SQNP01 data,
the subdistribution hazard analysis requires many
Table 5 Total number of events required, e, and total
sample size, n, for detecting various effect sizes for Event
M (distant metastasis)
Variables Cause-specific
hazard
Subdistribution
hazard
csHR e n subHR e n
Nodal status (Absent, Present) 0.40 38 153 0.39 38 231
Treatment (CRT, RT) 0.43 45 209 0.43 45 274
Tumour size (1, 2-4) 0.71 268 1209 0.75 379 2304
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even for the same magnitude of effect. As noted by
Latouche et al. [16], the cause-specific hazard ratio dif-
fered from the subdistribution hazard ratio due to dif-
ferences in the estimation of the cumulative incidence.
For the former, it is based on 1 - Kaplan Meier survi-
val estimates, which have been shown to overestimate
the cumulative incidence [28]. The bias increases with
time, and may be large for uncensored data, or for
data whereby a large proportion of subjects fail from
extraneous causes prior to the occurrence of the event
of interest [8]. As such, differences in sample estimates
between the two approaches are to be expected.
Although we have implemented the competing risks
methodology specifically in nasopharyngeal cancer, it is
widely applicable to other clinical settings such as epi-
lepsy, Parkinson’s disease or migraine, where more than
one primary event may be of interest when evaluating
the withdrawal of drug due to lack of efficacy and toler-
ability [24].
Conclusions
The cause-specific hazard analysis may be appropriate
when treatment has no effect on the cause-specific
hazard of the competing event. However, if the main
and competing events are influenced in opposing direc-
tions by an intervention, a subdistribution hazard analy-
sis may be warranted. The design of clinical trials
involving competing risks endpoints requires careful
planning and the choice of the statistical models used
should be made a priori to take into account such
considerations.
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